Formycon Signs APAC Eylea Biosimilar Deal With Taiwan’s Lotus

The Aflibercept Deal Follows A Flurry Of Approvals In The Past Year

Having secured approvals for the Eylea biosimilar in major markets such as the US and Europe, Formycon has signed a fresh licensing deal with Lotus Pharmaceutical, giving away rights to the asset in the APAC region.

join Scrip's APAC regional team for a video overview of recent industry topics and trends • Source: Shutterstock

Formycon and its licensing partner Klinge have signed a deal with Taiwan-headquartered player Lotus Pharmaceutical for commercialization rights to Formycon’s Eylea (aflibercept) biosimilar FYB203 in multiple countries in the Asia-Pacific region.

Signed for an undisclosed sum, the deal will hand over commercialization rights to Lotus in countries such as Indonesia, Malaysia and the Philippines. The agreement will also enable Lotus to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Formycon Signs APAC Eylea Biosimilar Deal With Taiwan’s Lotus

The Aflibercept Deal Follows A Flurry Of Approvals In The Past Year

Read the full article – start your free trial today!

More from Deals

More from Generics Bulletin